Abstract
A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have